|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Trabert B, DeSantis CE, Miller
KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL:
Ovarian cancer statistics, 2018. CA Cancer J Clin. 68:284–296.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hussain M, Zhou Y, Song Y, Hameed HMA,
Jiang H, Tu Y and Zhang J: ATAD2 in cancer: A pharmacologically
challenging but tractable target. Expert Opin Ther Targets.
22:85–96. 2018. View Article : Google Scholar
|
|
5
|
Boussouar F, Jamshidikia M, Morozumi Y,
Rousseaux S and Khochbin S: Malignant genome reprogramming by
ATAD2. Biochim Biophys Acta. 1829:1010–1014. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pollack JR, Sørlie T, Perou CM, Rees CA,
Jeffrey SS, Lonning PE, Tibshirani R, Botstein D, Børresen-Dale AL
and Brown PO: Microarray analysis reveals a major direct role of
DNA copy number alteration in the transcriptional program of human
breast tumors. Proc Natl Acad Sci USA. 99:12963–12968. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kalashnikova EV, Revenko AS, Gemo AT,
Andrews NP, Tepper CG, Zou JX, Cardiff RD, Borowsky AD and Chen HW:
ANCCA/ATAD2 overexpression identifies breast cancer patients with
poor prognosis, acting to drive proliferation and survival of
triple-negative cells through control of B-Myb and EZH2. Cancer
Res. 70:9402–9412. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hou M, Huang R, Song Y, Feng D, Jiang Y
and Liu M: ATAD2 overexpression is associated with progression and
prognosis in colorectal cancer. Jpn J Clin Oncol. 46:222–227. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Krakstad C, Tangen IL, Hoivik EA, Halle
MK, Berg A, Werner HM, Ræder MB, Kusonmano K, Zou JX, Øyan AM, et
al: ATAD2 overexpression links to enrichment of B-MYB-translational
signatures and development of aggressive endometrial carcinoma.
Oncotarget. 6:28440–28452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang M, Zhang C, Du W, Yang X and Chen Z:
ATAD2 is overexpressed in gastric cancer and serves as an
independent poor prognostic biomarker. Clin Transl Oncol.
18:776–781. 2016. View Article : Google Scholar
|
|
11
|
Lu WJ, Chua MS and So SK: Suppression of
ATAD2 inhibits hepatocellular carcinoma progression through
activation of p53- and p38-mediated apoptotic signaling.
Oncotarget. 6:41722–41735. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hong S, Bi M, Yan Z, Sun D, Ling L and
Zhao C: Silencing of ATPase family AAA domain-containing protein 2
inhibits migration and invasion of colorectal cancer cells.
Neoplasma. 63:846–855. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zheng L, Li T, Zhang Y, Guo Y, Yao J, Dou
L and Guo K: Oncogene ATAD2 promotes cell proliferation, invasion
and migration in cervical cancer. Oncol Rep. 33:2337–2344. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Caron C, Lestrat C, Marsal S, Escoffier E,
Curtet S, Virolle V, Barbry P, Debernardi A, Brambilla C, Brambilla
E, et al: Functional characterization of ATAD2 as a new
cancer/testis factor and a predictor of poor prognosis in breast
and lung cancers. Oncogene. 29:5171–5181. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Morozumi Y, Boussouar F, Tan M, Chaikuad
A, Jamshidikia M, Colak G, He H, Nie L, Petosa C, de Dieuleveult M,
et al: Atad2 is a generalist facilitator of chromatin dynamics in
embryonic stem cells. J Mol Cell Biol. 8:349–362. 2016. View Article : Google Scholar :
|
|
16
|
Liu J, Liu Z, Liu Q, Li L, Fan X, Wen T
and An G: CLEC3B is downregulated and inhibits proliferation in
clear cell renal cell carcinoma. Oncol Rep. 40:2023–2035.
2018.PubMed/NCBI
|
|
17
|
Tan TZ, Yang H, Ye J, Low J, Choolani M,
Tan DS, Thiery JP and Huang RY: CSIOVDB: A microarray gene
expression database of epithelial ovarian cancer subtype.
Oncotarget. 6:43843–43852. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yoshihara K, Tajima A, Komata D, Yamamoto
T, Kodama S, Fujiwara H, Suzuki M, Onishi Y, Hatae M, Sueyoshi K,
et al: Gene expression profiling of advanced-stage serous ovarian
cancers distinguishes novel subclasses and implicates ZEB2 in tumor
progression and prognosis. Cancer Sci. 100:1421–1428. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bowen NJ, Walker LD, Matyunina LV, Logani
S, Totten KA, Benigno BB and McDonald JF: Gene expression profiling
supports the hypothesis that human ovarian surface epithelia are
multipotent and capable of serving as ovarian cancer initiating
cells. BMC Med Genomics. 2:712009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mok SC, Bonome T, Vathipadiekal V, Bell A,
Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, et al: A
gene signature predictive for outcome in advanced ovarian cancer
identifies a survival factor: Microfibril-associated glycoprotein
2. Cancer. Cell. 16:521–532. 2009.
|
|
21
|
Emanuelsson O, Nagalakshmi U, Zheng D,
Rozowsky JS, Urban AE, Du J, Lian Z, Stolc V, Weissman S, Snyder M
and Gerstein MB: Assessing the performance of different
high-density tiling microarray strategies for mapping transcribed
regions of the human genome. Genome Res. 17:886–897. 2007.
View Article : Google Scholar :
|
|
22
|
Mermel CH, Schumacher SE, Hill B, Meyerson
ML, Beroukhim R and Getz G: GISTIC2.0 facilitates sensitive and
confident localization of the targets of focal somatic copy-number
alteration in human cancers. Genome Biol. 12:R412011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: A cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBio-Portal. Sci Signal. 6:pl12013. View Article : Google Scholar
|
|
25
|
Prat J; FIGO Committee on Gynecologic
Oncology: Staging classification for cancer of the ovary, fallopian
tube, and peritoneum: Abridged republication of guidelines from the
international federation of gynecology and obstetrics (FIGO).
Obstet Gynecol. 126:171–174. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Trimarchi JM, Stadler MB and Cepko CL:
Individual retinal progenitor cells display extensive heterogeneity
of gene expression. PLoS One. 3:e15882008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gyorffy B, Lánczky A and Szállási Z:
Implementing an online tool for genome-wide validation of
survival-associated biomarkers in ovarian-cancer using microarray
data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ferriss JS, Kim Y, Duska L, Birrer M,
Levine DA, Moskaluk C, Theodorescu D and Lee JK: Multi-gene
expression predictors of single drug responses to adjuvant
chemotherapy in ovarian carcinoma: Predicting platinum resistance.
PLoS One. 7:e305502012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bonome T, Levine DA, Shih J, Randonovich
M, Pise-Masison CA, Bogomolniy F, Ozbun L, Brady J, Barrett JC,
Boyd J and Birrer MJ: A gene signature predicting for survival in
suboptimally debulked patients with ovarian cancer. Cancer Res.
68:5478–5486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Konstantinopoulos PA, Spentzos D, Karlan
BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA and Cannistra
SA: Gene expression profile of BRCAness that correlates with
responsiveness to chemotherapy and with outcome in patients with
epithelial ovarian cancer. J Clin Oncol. 28:3555–3561. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lisowska KM, Olbryt M, Dudaladava V,
Pamuła-Piłat J, Kujawa K, Grzybowska E, Jarząb M, Student S,
Rzepecka IK, Jarząb B and Kupryjańczyk J: Gene expression analysis
in ovarian cancer-faults and hints from DNA microarray study. Front
Oncol. 4:62014. View Article : Google Scholar
|
|
32
|
Mateescu B, Batista L, Cardon M, Gruosso
T, de Feraudy Y, Mariani O, Nicolas A, Meyniel JP, Cottu P,
Sastre-Garau X and Mechta-Grigoriou F: miR-141 and miR-200a act on
ovarian tumorigenesis by controlling oxidative stress response. Nat
Med. 17:1627–1635. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tothill RW, Tinker AV, George J, Brown R,
Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro
B, et al: Novel molecular subtypes of serous and endometrioid
ovarian cancer linked to clinical outcome. Clin Cancer Res.
14:5198–5208. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Makii C, Oda K, Ikeda Y, Sone K, Hasegawa
K, Uehara Y, Nishijima A, Asada K, Koso T, Fukuda T, et al: MDM2 is
a potential therapeutic target and prognostic factor for ovarian
clear cell carcinomas with wild type TP53. Oncotarget.
7:75328–75338. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Koti M, Gooding RJ, Nuin P, Haslehurst A,
Crane C, Weberpals J, Childs T, Bryson P, Dharsee M, Evans K, et
al: Identification of the IGF1/PI3K/NF κB/ERK gene signalling
networks associated with chemotherapy resistance and treatment
response in high-grade serous epithelial ovarian cancer. BMC
Cancer. 13:5492013. View Article : Google Scholar
|
|
36
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee SJ, Bae JH, Lee AW, Tong SY, Park YG
and Park JS: Clinical characteristics of metastatic tumors to the
ovaries. J Korean Med Sci. 24:114–119. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Saha A, Kim Y, Gewirtz ADH, Jo B, Gao C,
McDowell IC; GTEx Consortium; Engelhardt BE and Battle A:
Co-expression networks reveal the tissue-specific regulation of
transcription and splicing. Genome Res. 27:1843–1858. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
van Dam S, Võsa U, van der Graaf A, Franke
L and de Magalhães JP: Gene co-expression analysis for functional
classification and gene-disease predictions. Brief Bioinform.
19:575–592. 2018.
|
|
40
|
Zhang W and Liu HT: MAPK signal pathways
in the regulation of cell proliferation in mammalian cells. Cell
Res. 12:9–18. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shlien A and Malkin D: Copy number
variations and cancer. Genome Med. 1:622009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ciró M, Prosperini E, Quarto M, Grazini U,
Walfridsson J, McBlane F, Nucifero P, Pacchiana G, Capra M,
Christensen J and Helin K: ATAD2 is a novel cofactor for MYC,
overexpressed and amplified in aggressive tumors. Cancer Res.
69:8491–8498. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wu G, Lu X, Wang Y, He H, Meng X, Xia S,
Zhen K and Liu Y: Epigenetic high regulation of ATAD2 regulates the
Hh pathway in human hepatocellular carcinoma. Int J Oncol.
45:351–361. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zou JX, Guo L, Revenko AS, Tepper CG, Gemo
AT, Kung HJ and Chen HW: Androgen-induced coactivator ANCCA
mediates specific androgen receptor signaling in prostate cancer.
Cancer Res. 69:3339–3346. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zou JX, Revenko AS, Li LB, Gemo AT and
Chen HW: ANCCA, an estrogen-regulated AAA+ ATPase coactivator for
ERalpha, is required for coregulator occupancy and chromatin
modification. Proc Natl Acad Sci USA. 104:18067–18072. 2007.
View Article : Google Scholar : PubMed/NCBI
|
